Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091551 | 1.00 | PRKCA (0.49) | PRKCAL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL2761788 | 0.89 | MAOB (0.43) | PRKCAL3MBTL1MAPTTDP1MAOB | |
| SCHEMBL2762045 | 0.89 | MAOB (0.41) | PRKCAL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL1949049 | 0.88 | NPC1 (0.43) | PRKCAL3MBTL1MAPTTDP1MAOB | |
| SCHEMBL15356467 | 0.83 | CETP (0.41) | PRKCAL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL31013857 | 0.83 | MAOB (0.41) | PRKCAL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL31014009 | 0.82 | L3MBTL1 (0.46) | PRKCAL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL15348536 | 0.81 | TDP1 (0.51) | L3MBTL1TDP1MAOBHTR1ADRD2 | |
| SCHEMBL15349916 | 0.80 | ALDH1A1 (0.39) | PRKCAL3MBTL1MAPK1TDP1ALDH1A1 | |
| SCHEMBL31562853 | 0.80 | MAOB (0.44) | PRKCAL3MBTL1MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20220388996-A1 | METHODS OF MAKING A MODULATOR OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3632919-B1 | PHARMACEUTICAL COMPOISITIONS COMPRISING IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2022-10-26 | — | — | EP | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2013163248-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163279-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| WO-2013163248-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | PRKCA 2888/4885L3MBTL1 3317/4885MAPT 1067/4885 |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | PRKCA 1689/4885L3MBTL1 1492/4885MAPT 4374/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | PRKCA 2836/4885L3MBTL1 3305/4885MAPT 990/4885 |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, F2R, TMPRSS4 | PRKCA 2836/4885L3MBTL1 3305/4885MAPT 990/4885 |
| US-20220388996-A1 | METHODS OF MAKING A MODULATOR OF HEMOGLOBIN | HBB, HBG1, HBG2 | PRKCA 1378/4885L3MBTL1 4072/4885MAPT 4799/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | PRKCA 2888/4885L3MBTL1 3317/4885MAPT 1067/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | PRKCA 2769/4885L3MBTL1 3352/4885MAPT 1032/4885 |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | PRKCA 1343/4885L3MBTL1 3898/4885MAPT 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.